• Low-risk investment model: Royalty-based business model with key partnerships with pharmaceutical giants such as Teva and AbbVie, reducing operational and market risks.
• Innovative product development: Developed and patented a novel delivery method that can improve treatment adherence for schizophrenia.
• Growth potential: Potential expansion into new treatments, with an R&D pipeline fully funded by external companies.
Investment thesis: Medincell offers an attractive long opportunity, benefiting from product adoption while significantly mitigating operational risks through third-party partnerships.